Company intelligence / Profile preview

Adan Medical Innovation

Barcelona, Catalonia, Spainadanmi.com ↗

Ownership: Private
Development stage: Commercial

Overview

Adan Medical Innovation has developed "anAPPhylaxis," a smart case and mobile app system for people who must carry two epinephrine autoinjectors due to risk of anaphylaxis. A six-month clinical study with about 100 patients showed the technology improved compliance, reduced anaphylactic events, and enhanced quality of life. The product holds CE Mark approval in Europe. Additional products include a smartwatch version targeting pediatric populations and "WE SAVE," a smartbox solution for public spaces.

Therapeutic areas: Immunology
Modalities: DeviceMobile app/digital solution
Industry: Digital Health Medical Devices

Drug pipeline

2 assets

AnAPPhylaxis

Commercial

Indications: Anaphylaxis

1 more asset in the full pipeline.

Request access →

Beyond the preview

Go deeper on Adan Medical Innovation.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Adan Medical Innovation.

Explore the full profile